The Offensive Line - Okung Could Miss All Of Camp

[wu-dai clan]

So the Oline will be fine.
Okung had blood clots.
I called it.

[like54ninjas]

In a statement posted to Twitter, Okung wrote the following:

"We all know injuries are part of the game, but I wanted to share some current details about my current health status which is quite different than previous 'injury' scenarios I've experienced in my career.

"After experiencing unusual chest pain at practice on June 1st, I went to urgent care out of an abundance of caution. According to the doctors who treated me, the decision to do so likely saved my life.

"Thankfully, I'm okay now, but a few tests revealed that I suffered a Pulmonary Embolism caused by blood clots. When detected early, this condition is very treatable and I'm grateful to have access to the best available care as I continue on the path to full recovery.

"I'm very grateful to my teammates, coaches and the entire Chargers organization for their care, support and understanding during this challenging situation. Thanks to an incredible medical team and a very supportive family, I hope to be back on the field as quickly as possible.

"While near death type experiences are certainly a wake-up call, I'm feeling great physically. It's not an ankle or shoulder. As soon as doctors clear me, my plans include blocking #17's [Philip Rivers'] blind side all the way to Miami."

Super Bowl LIV will be played in Miami. What is a pulmonary embolism?

A pulmonary embolism is a blockage in one of the pulmonary arteries in the lungs.

Via the Mayo Clinic, in most cases, pulmonary embolism is caused by blood clots that travel to the lungs from the legs, though rarely the clots come from other parts of the body.

Because clots block blood flow to the lungs, they can be life-threatening. As Okung noted, getting treatment quickly may have saved his life - about one-third of people with undiagnosed and untreated pulmonary embolism die.

Treatments can include medications like blood thinners and clot-dissolvers or surgical clot removal. At camp with teammates

Sam TeviTrey Pipkins in the third round this year.

[jamrock]

So the Oline will be fine.
Okung had blood clots.
I called it.

Yeah you did. Amazing. Are u in with Russell?

[wu-dai clan]

Yeah you did. Amazing. Are u in with Russell?

I called "blood clots" hours ago.
Can I go now ?
Dr Chao is on line 2.

[Formula 21]

Yeah you did. Amazing. Are u in with Russell?

Hell, are you with the Russians?

[Sgt. Pepper]

African American men are more at risk for pulmonary embolism. Another risk factor for embolism for Okung is the extra weight he must carry as an NFL lineman. When he is done playing, hope he does what Nick Hardwick did and sheds his excess playing poundage to get down to a more normal and healthy body weight. Hardwick dropped 85 lbs after he retired.

All that said, godspeed to you Russell Okung for a speedy recovery, first for your health and longevity and second to get back on the field to help the Chargers win the Lombardi this season.

[Formula 21]

Russell Okung signed a 4 year, $53,000,000 contract with the Los Angeles Chargers, including a $10,000,000 signing bonus, $25,000,000 guaranteed, and an average annual salary of $13,250,000. In 2019, Okung will earn a base salary of $13,000,000 and a roster bonus of $468,750, while carrying a cap hit of $15,968,750 and a dead cap value of $5,000,000.

Contract Terms: 4 yr(s) / $53,000,000

Signing Bonus $10,000,000

Average Salary$13,250,000

GTD at Sign:$25,000,000

Total GTD:$25,000,000

Free Agent:2021 / UFA

2017		29	$3,000,000	$2,500,000	$500,000	$6,000,000	$25,000,000	$13,468,750($13,468,750)
2018		30	$12,000,000	$2,500,000	$468,750	$14,968,750	$19,500,000	$12,468,750($25,937,500)
Potential Out: 2019, 2 yr, $25,937,500; $5,000,000 dead cap
2019		31	$13,000,000	$2,500,000	$468,750	$15,968,750	$5,000,000	$13,468,750($39,406,250)
2020		32	$13,000,000	$2,500,000	$500,000	$16,000,000	$2,500,000	$13,500,000($52,906,250)
	Contract Notes: $25M guaranteed at signing (signing bonus + 2017 salary + 2018 salary) 2017 Per Game Active Bonus: $31,250 ($500,000) 2018 Per Game Active Bonus: $31,250 ($500,000, 15 LTBE) 2019 Per Game Active Bonus: $31,250 ($500,000, 15 LTBE) 2020 Per Game Active Bonus: $31,250 ($500,000)

[Formula 21]

Bolts are on the hook for $26 million even if Okung never recovers enough to play if he stays on he squad. A distinct possibility.

One notable difference between the NFI and PUP lists is that the team has the right to not pay base salary to a player on the NFI list. The idea is that if a player suffered his injury outside the purview of the team, they should not be responsible for his salary. However, teams will often work out deals with NFI players to pay some or all of their salary when there is a common understanding about the injury. This is particularly true with players who the team knows will go on the NFI list upon arrival to the team.

I don't know, but if the Bolts can get out of their contract with minimal cap hit and cash out, they have to do it.

[Bolt-O]

oh my. PE's are just as bad as STEMIs, only that muscle may not be dead, but can kill you as fast. The blood thinner will make bruising and bleeding easier, and that's not good for a guy in a constant sumo match. Maybe not as hard a collision, but a big guy getting thrown around to the ground isn't good.

We will need a replacement for at least this season.

[chargeroo]

All of a sudden the "loaded roster" isn't looking so loaded. Without Okung and Gordon the offense will in big trouble.

[Formula 21]

The QBs best friends, the OLT and RB. Gone for now.

[Formula 21]

Patients Who Develop Blood Clots At Risk Of Recurrence Within Three Years

Date: February 25, 2008 Source: JAMA and Archives Journals Summary: Patients who develop a blood clot in their legs (deep vein thrombosis) or lungs (pulmonary embolism) are at risk for experiencing another blood clot within three years, and patients with pulmonary embolism have a higher risk of death. Share:
FULL STORY

---

Patients who develop a blood clot in their legs (deep vein thrombosis) or lungs (pulmonary embolism) are at risk for experiencing another blood clot within three years, and patients with pulmonary embolism have a higher risk of death, according to a new report.
Deep vein thrombosis and pulmonary embolism are considered different manifestations of the same disease process, according to background information in the article. The medical management of both conditions, known collectively as venous thromboembolism, has improved in the past decade, the authors note.
Frederick A. Spencer, M.D., of McMaster University Medical Center, Hamilton, Ontario, Canada, and colleagues analyzed the medical records of 1,691 Worcester, Mass., residents (54 percent women, average age 65) who were diagnosed with venous thromboembolism in 1999, 2001 or 2003. Of those, 549 had pulmonary embolism and 1,142 had isolated deep vein thrombosis.
Over the three-year study, among the 549 patients who presented with pulmonary embolism, 31 (5.7 percent) had a recurrent clot in the lung, 75 (13.7 percent) had a recurrence of either type of venous thromboembolism and 82 (14.9 percent) experienced a major bleeding episode (i.e., so severe they required a transfusion). Among the 1,142 patients who presented with isolated deep vein thrombosis over the same period, 64 (5.6 percent) developed a pulmonary embolism, 217 (19 percent) had recurrent venous thromboembolism and 146 (12.8 percent) had a major bleeding episode.
Individuals with pulmonary embolism were more likely to die after one month (13 percent vs. 5.4 percent), one year (26 percent vs. 20.3 percent) and three years (35.3 percent vs. 29.6 percent) than those with deep vein thrombosis. "Patients whose course was complicated by major bleeding were more likely to experience recurrent venous thromboembolism or to die at three years than those without these complications," the authors write.
"Patients who presented with pulmonary embolism had similar rates of subsequent pulmonary embolism or recurrent venous thrombosis compared with patients with isolated deep vein thrombosis," the authors conclude. "However, rates of recurrent venous thromboembolism and major bleeding after deep vein thrombosis and pulmonary embolism remain unacceptably high in the community setting. Efforts are needed to identify patients most at risk for venous thrombosis--associated complications and to develop better anticoagulation strategies conducive to long-term use in the community setting."
Journal reference: Arch Intern Med. 2008;168[4]:425-430.
This study was supported by a grant from the National Heart, Lung and Blood Institute.

That's 34.3% who have a recurrence.